{"id":"NCT00838526","sponsor":"Eisai Inc.","briefTitle":"Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)","officialTitle":"Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08-31","primaryCompletion":"2009-07-31","completion":"2009-12-31","firstPosted":"2009-02-06","resultsPosted":"2015-06-23","lastUpdate":"2022-04-25"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gastroesophageal Reflux Disease (GERD)"],"interventions":[{"type":"DRUG","name":"Rabeprazole ER","otherNames":["Aciphex"]},{"type":"DRUG","name":"Ranitidine","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy of rabeprazole extended release (ER) 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (eGERD).","primaryOutcome":{"measure":"Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26","timeFrame":"Baseline to Week 26","effectByArm":[{"arm":"RAN 150mg BID","deltaMin":32.9,"sd":null},{"arm":"RAB ER 50mg QD","deltaMin":84.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":59},"commonTop":["Gastritis","Nausea","Sinusitis","Hiatus hernia"]}}